Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Ther Clin Risk Manag · 2007 · PMC2387294 · PMID 18516265

Europe PMC

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

just failed to reach statistical significancep = 0.054so close (0.05 < p ≤ 0.1)

ADAS-Cog scores also improved in patients receiving rivastigmine bid compared with the placebo, but just failed to reach statistical significance (p = 0.054).

also in 203 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.